Loading
WuXi Biologics (Cayman) Inc. Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Chen Zhisheng, was filed 31 Mar 2026.
Insider Decl.
551
Thresholds
n/a
Buy Volume
€35M
47 ops. · all time
Sell Volume
€12B
223 ops. · all time
Who traded when
BuySaleChen Zhisheng3 buys24 sales
Zhou Weichang7 sales
Li Ge3 sales
Gu Sherry Xuejun1 buy1 sale
Since the insiders bought
- +41.7%Entry HK$34.86 · Close 21 Oct 2026 HK$49.40
- +41.7%Entry HK$34.86 · Close 21 Oct 2026 HK$49.40
- +104.9%Entry HK$12.20 · Close at T+365 HK$25.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate WuXi Biologics (Cayman) Inc. Strong Buy (bullish), based on 23 analysts. Average price target: HK$60.22.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 10,036 of 26,284 companies
57.4
score / 100
Value38
Quality77
FCF yld1.4%
Earn yld2.6%
EV/EBITDA21.7x
ROE11%
Gross mgn46%
Net mgn23%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$49.50
Analyst consensus
23 analystsStrong buy
HK$39.37Target HK$60.22(+22%)HK$79.59
Income statement
RevenueHK$21.8B
Gross profitHK$10B46% margin
EBITDAHK$8.8B41% margin
Net incomeHK$4.9B21.2% margin
Valuation
PER (trailing)37.2x
PER (forward)26.6x
P/Book3.6x
Beta0.59
Balance sheet & cash
Market capHK$203.8B
Total debtHK$3.1B
Free Cash FlowHK$2.6B
Debt / Equity5%
Profitability & ownership
ROE11.4%
ROA7.6%
% insiders10.1%
% institutions36.7%
Last declaration on 20 October 2026
Declarations551 total
90,000,000 shares@ HK$52.312.38% mcap4.6% of flowShareXHKGHKEX:DA20261016E00531
90,000,000 sharesShareXHKGHKEX:DA20261014E00644
1,200,000 shares@ HK$49.13590.029% mcap1.7% of flowShareXHKGHKEX:DA20260916E00540
1,200,000 shares@ HK$2.63670.0015% mcap0.1% of flowShareXHKGHKEX:DA20260914E00530
1,800,090 shares@ HK$49.03680.043% mcap2.6% of flowShareXHKGHKEX:DA20260914E00529
3,200,000 shares@ HK$49.38530.077% mcap4.6% of flowShareXHKGHKEX:DA20260911E00662
1,800,090 shares@ HK$2.63670.0023% mcap0.1% of flowShareXHKGHKEX:DA20260910E00390
2,400,000 shares@ HK$50.54490.059% mcap3.6% of flowShareXHKGHKEX:DA20260910E00389
1,500,000 shares@ HK$49.14080.035% mcap2.2% of flowShareXHKGHKEX:DA20260909E00596
3,200,000 shares@ HK$2.63670.0040% mcap0.2% of flowShareXHKGHKEX:DA20260909E00597
2,400,000 shares@ HK$2.63670.0030% mcap0.2% of flowShareXHKGHKEX:DA20260908E00492
1,500,000 shares@ HK$2.63670.0018% mcap0.8% of flowShareXHKGHKEX:DA20260907E00497
104,495 sharesShareXHKGHKEX:DA20260827E00572
15,117 sharesShareXHKGHKEX:DA20260827E00575
378,080 sharesShareXHKGHKEX:DA20260622E00526
264,866 sharesShareXHKGHKEX:DA20260615E00437
29,677 sharesShareXHKGHKEX:DA20260615E00438
148,127 sharesShareXHKGHKEX:DA20260401E00525
16,724 sharesShareXHKGHKEX:DA20260401E00527
1,442,769 sharesShareXHKGHKEX:DA20260330E00499
Canonical exit: 23 Jun 2026 (T+90)
543,819 sharesShareXHKGHKEX:DA20260330E00501
Canonical exit: 23 Jun 2026 (T+90)
54,838 sharesShareXHKGHKEX:DA20260330E00500
Canonical exit: 23 Jun 2026 (T+90)
1,734 sharesShareXHKGHKEX:DA20260327E00406
6,713 sharesShareXHKGHKEX:DA20260326E00431
150,000,000 shares@ HK$38.525.7% of flowShareXHKGHKEX:DA20260123E00723
25 of 551 declarations
About WuXi Biologics (Cayman) Inc.
WuXi Biologics, a healthcare group listed in Hong Kong (HKD 203.8 billion market capitalisation, 10.1% of the capital held by insiders), has 551 filings between December 19, 2017 and October 20, 2026, from 11 filers. Selling dominates by count: 234 sales against 47 purchases, or 17% purchases, with 270 other filings on top. The 17 purchases with an amount total EUR 34.9 million, median EUR 374,708.
Li Ge, a director, is the most frequent filer: 282 filings, 152 of them sales and 5 purchases. The EUR 17.7 million purchase on January 24, 2024 is the largest in the record; director Chen Zhisheng follows with EUR 4.3 million on November 4, 2021 and EUR 2.4 million on December 16, 2021, and has 114 filings (14 purchases, 35 sales). Zhou Weichang has 64 (7 purchases, 21 sales), Zhao Ning 19 (10 sales).
Read moreShow less
On June 10, 2022, 5 insiders filed on the same day. Yearly volume rises to 192 in 2019 and falls back to 23 in 2024 and 61 in 2025. For 20 purchases a 90-day result is stored: a median of 6.3%, with 55% positive (recorded past results, not a forecast). In the last twelve months: 59 filings, 3 purchases, 21 sales. Publication takes a median of 3 days.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
